SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Jennifer I. Lim, MD, discusses the effect of faricimab on pigment epithelial detachments.
Patients received monthly doses of either faricimab or aflibercept for the treatment of neovascular age-related macular degeneration. After 12 weeks, Lim and colleagues evaluated the drying effect of each drug.
Lim said there was not a difference between the two groups with fibrovascular pigment epithelial detachments (PEDs), but in serous PEDs, 3.9% of eyes treated with faricimab still had a serous PED component compared with